While AMI treated P301S mice demonstrated significant decrease in the levels of MYD88, NF-KB, TNF-α and IL-22 by 52% (P < 0.0001, F (2,15) = 770.9), 54% (P < 0.0001, F (2,15) = 794.5), 49% (P < 0.0001, F (2,15) = 385.6) and 39% (P < 0.0001, F (2,15) = 668.8) respectively when compared to tauopathy model (Fig. 12f-i). The gene discussed is IL22; the disease is tauopathy.